- DREADD agonist 21
-
- $37.00
-
2026-07-27
- CAS:56296-18-5
- Purity: 99.94%
- Supply Ability: 10g
- DREADD agonist 21
-
- $37.00
-
2026-07-27
- CAS:56296-18-5
- Purity: 99.94%
- Supply Ability: 10g
|
| | 11-Piperazinyldibenzo[b,e][1,4]diazepine Basic information |
| Product Name: | 11-Piperazinyldibenzo[b,e][1,4]diazepine | | Synonyms: | 11-Piperazinyldibenzo[b,e][1,4]diazepine;11-(1-Piperazinyl)-5H-dibenzo[b,e][1,4]diazepine;DREADD agonist 1;5H-Dibenzo[b,e][1,4]diazepine, 11-(1-piperazinyl)-;Muscarinic acetylcholine receptor,schizophrenia,mAChR,Inhibitor,muscarinic,disease,inhibit,DREADD agonist21,neurodegenerative,acetylcholine,DREADD agonist 21,DREADD,neuronal,hM3Dq,DREADD agonist-21,activation,receptors;11-(Piperazin-1-yl)-5H-dibenzo[b,e][1,4]diazepine;DREADD Agonist 21, DREADD agonist;DREADD agonist 21, 10 mM in DMSO | | CAS: | 56296-18-5 | | MF: | C17H18N4 | | MW: | 278.35 | | EINECS: | | | Product Categories: | | | Mol File: | 56296-18-5.mol | ![11-Piperazinyldibenzo[b,e][1,4]diazepine Structure](CAS/20150408/GIF/56296-18-5.gif) |
| | 11-Piperazinyldibenzo[b,e][1,4]diazepine Chemical Properties |
| Melting point | 230-234 °C(Solvent: Methanol) | | Boiling point | 470.1±55.0 °C(Predicted) | | density | 1.28±0.1 g/cm3(Predicted) | | storage temp. | Store at -20°C | | solubility | DMSO:PBS (pH 7.2) (1:1):0.5(Max Conc. mg/mL);1.8(Max Conc. mM)
Ethanol:29.61(Max Conc. mg/mL);106.39(Max Conc. mM) | | form | A crystalline solid | | pka | 8.56±0.10(Predicted) | | color | Yellow | | Water Solubility | H2O: 2mg/mL, clear | | InChI | 1S/C17H18N4/c1-2-6-14-13(5-1)17(21-11-9-18-10-12-21)20-16-8-4-3-7-15(16)19-14/h1-8,18-19H,9-12H2 | | InChIKey | JCBYXNSOLUVGTF-UHFFFAOYSA-N | | SMILES | C1(C=CC=C2)=C2C(N3CCNCC3)=NC(C=CC=C4)=C4N1 |
| WGK Germany | WGK 3 | | Storage Class | 11 - Combustible Solids | | Hazard Classifications | Acute Tox. 4 Oral |
| | 11-Piperazinyldibenzo[b,e][1,4]diazepine Usage And Synthesis |
| Description | DREADD agonist 21 activates hM3Dq (EC50 = 1.7 nM), a designer receptor exclusively activated by designer drugs (DREADD) derived from the human muscarinic acetylcholine M3 receptor. It does not agonize the hM3 receptor and displays relatively weaker binding affinities for serotonin 5-HT2A, 5-HT2C, α1A-adrenergic, and histamine H1 receptors (Kis = 66, 170, 280, and 6 nM, respectively). | | Uses | DREADD agonist 21 is an agonist of hM3Dq, a designer receptor exclusively activated by designer drugs (DREADD). It preferentially binds hM3DqDREADDs over endogenous hM3receptors. | | in vivo | DREADD agonist 21 (0.3, 1.0, and 3.0 mg/kg; i.p.) activates neuronal hM3Dq in mice[2].
DREADD agonist 21 has excellent bioavailability, pharmacokinetic properties, and brain penetrability. DREADD agonist 21 (0.1, 1, and 10 mg/kg; i.p.) displays 95.1% plasma protein binding and 95% brain protein bounding in mice[2]. | | IC 50 | mAChR3 | | storage | Room temperature | | References | [1] XIN CHEN. The First Structure–Activity Relationship Studies for Designer Receptors Exclusively Activated by Designer Drugs[J]. ACS Chemical Neuroscience, 2015, 6 3: 476-484. DOI: 10.1021/cn500325v |
| | 11-Piperazinyldibenzo[b,e][1,4]diazepine Preparation Products And Raw materials |
|